

# ***Basingstoke, Southampton and Winchester***

## ***District Prescribing Committee (DPC)***

### **Recommendations of the meeting of Tuesday 9th October 2018**

#### **Supported or limited support e.g. Specialist recommendation**

**Bezafibrate (400mg MR tablets)** for Primary Biliary Cholangitis (PBC)- Based on scientific evaluation of the evidence for efficacy, safety and cost effectiveness the committee supports this off label use of Bezafibrate for PBC.

It may be considered as an alternative to Obeticholic acid (OCA), to be used in combination with Ursodeoxycholic acid (UDCA) in patients with inadequate response or as monotherapy in patients intolerant of UDCA. It should be recommended by specialists. Consider adding to formularies as 'AMBER'

#### **Not supported**

**Trimovate® cream for chronic wound management-** Based on scientific evaluation of the evidence for efficacy, safety and cost effectiveness the committee do not support use of Trimovate cream for chronic wound management. Use for other indications will be discussed with Dermatology.

#### **Other Information and formulary updates**

**Wessex Adult Asthma guidelines-** These guidelines have been agreed for use locally. They can be found on the link below.

**Stoma appliances formulary-** Southampton formulary update agreed for local use

**Epipen and Epipen Junior-** will be subject to limited availability for the remainder of 2018.

The MHRA issued an alert in September, a summary of the actions are listed below

- Adult and child auto-injectors should only prescribed and dispensed to those who truly need them
- Certain batches of adult EpiPen can be safely used for four months after the expiry date has passed.
- Patients should be advised not to dispose of their expired devices until they have replaced them.
- Patients may need to switch from their usual device to other alternative adrenaline auto-injector devices that may be more readily available. The different brands of adrenaline auto-injectors are not used in exactly the same way and therefore specific training and advice is required for each of the devices

For more information see [MHRA Epipen update September 2018](#)

**Rifaximin-** a shared care guideline has been agreed for the use of Rifaximin for the reduction in recurrence of episodes of overt hepatic encephalopathy in patient's  $\geq 18$  years of age. The guideline can be found at the link below

- Guidance documents are available [Here](#) (hosted by West Hampshire CCG)

**Summarised on behalf of the District Prescribing Committee by Andrea White (Southampton City CCG)**